Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Ranibizumab untuk edema makula diabetik

Penilaian teknologi kesehatan PTK-S01LA04 Draf untuk telaah Diperbarui 14 Juni 2026

1. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Ranibizumab sesuai kebutuhanRp 50,3 juta7,96211,82
laser makulaRp 27,8 juta7,55011,79
SelisihRp 22,5 juta0,412-

2. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
02040600,000,200,400,600,801,00Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta99,3%

3. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-20-1001020interventions ranibizumab PRN drug cost idr per courseinterventions ranibizumab PRN drug...transition rates annual bcva good to bcva moderatetransition rates annual bcva good ...transition rates annual bcva good to deadtransition rates annual bcva good ...utility values bcva goodutility values bcva goodinterventions macular laser transition rate multipliers bcva good to bcva moderateinterventions macular laser transi...transition rates annual bcva moderate to bcva poortransition rates annual bcva moder...utility values bcva moderateutility values bcva moderateinterventions ranibizumab PRN transition rate multipliers bcva good to bcva moderateinterventions ranibizumab PRN tran...utility values bcva poorutility values bcva poorinterventions macular laser transition rate multipliers bcva moderate to bcva poorinterventions macular laser transi...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

4. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (15 yr)0,412Rp 22,5 jutaRp 54,6 juta
5-year horizon0,051Rp 29,5 jutaRp 578,5 juta
10-year horizon0,206Rp 26,7 jutaRp 129,9 juta
0% discount rate0,559Rp 20,6 jutaRp 36,8 juta
5% discount rate0,340Rp 23,3 jutaRp 68,6 juta
Real-world under-treatment / fewer injections (ranibizumab vision-improvement effect x0.7)0,381Rp 22,9 jutaRp 60,2 juta
Ranibizumab biosimilar / lower acquisition price (-50% drug cost)0,412Rp 5,8 jutaRp 14,0 juta
Policy scenario: comparator = off-label bevacizumab assumed clinically equivalent (DRCR.net Protocol T); tests whether branded ranibizumab justifies its premium over the cheap LMIC alternative0,000Rp 28,2 jutaTidak dihitung

5. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).

Luaran pembandingPrediksi modelData terbitSumber
Annual progression to worse vision band under laser standard of care (moderate -> poor BCVA, treated eye)12,0%12,0%NICE TA274 / RESTORE laser-monotherapy arm: minimal mean BCVA gain (+0.8 letters) and a substantial proportion losing >=
Vision-threatening diabetic retinopathy / blindness incidence anchor (poor -> severe BCVA, comparator)10,0%8,3%Indonesian type-2-diabetes prospective cohort: blindness incidence 8.33 per 1000 person-years and vision-threatening DR
All-cause mortality at 10 years (type-2-diabetic DMO cohort, mean age ~62, comparator arm)27,8%36,0%Compounded ~3.5-5%/yr mortality for an older type-2-diabetic Indonesian cohort (diabetes relative risk applied to WHO/IH

6. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • Threshold: WHO-CHOICE proxy 1x PDB Rp 75 juta/QALY; 3x PDB Rp 225 juta/QALY (not an official InaHTAC threshold).
  • Primary comparator is macular laser photocoagulation because it is the pragmatic, JKN-reimbursable Indonesian standard of care for DMO and the NICE TA274 base comparator; off-label bevacizumab is included as the cheap real-world class-context comparator most relevant to LMIC practice and tested in scenario analysis.
  • DMO is the chosen indication (over wet AMD / RVO) because Indonesia carries one of the world's highest diabetic-retinopathy burdens (Asia range up to ~43%) on top of ~19.5 million people with diabetes, making DMO the largest anti-VEGF-eligible ophthalmic population.
  • NICE TA274 recommends ranibizumab for DMO only where central retinal thickness is >=400 micrometres and at a patient-access-scheme discount; this analysis adopts the >=400 micrometre cost-effective subgroup as the modelled population.
  • Ranibizumab (Lucentis) is BPOM-registered (NIE DKI0767506043A1, Novartis) and also supplied as the LMIC formulation Patizra; precise current Fornas/JKN listing and any restriction wording for anti-VEGF agents in DMO should be verified directly against the current Kepmenkes Formularium Nasional, which could not be confirmed from official text in this review.
  • A ranibizumab biosimilar and lower-priced anti-VEGF options materially change affordability and are tested in scenario analysis; the within-class value question (ranibizumab vs off-label bevacizumab) is the central budget-impact issue for Indonesia.